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Abstract
Background—Opiate use is common in HIV- and hepatitis C virus (HCV)-infected individuals,
however its contribution to the risk of diabetes mellitus is not well understood.
Methods—Prospective study of 1,713 HIV-infected and 652 uninfected participants from the
Women’s Interagency HIV Study between October 2000 and March 2006. Diabetes defined as
fasting glucose ≥126 mg/dl, or self-report of diabetes medication use or confirmed diabetes
diagnosis. Opiate use determined using an interviewer-administered questionnaire. Detectable
plasma HCV RNA confirmed HCV infection.
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Results—Current opiate users had a higher prevalence of diabetes (15%) than non-users (10%,
p=.03), as well as a higher risk of incident diabetes (adjusted relative hazard [RHadj] 1.58, 95% CI
1.01, 2.46), after controlling for HCV infection, HIV/antiretroviral therapy status and diabetes risk
factors including age, race/ethnicity, family history of diabetes and body mass index. HCV
infection was also an independent risk factor for diabetes (RHadj 1.61, 95% CI 1.02, 2.52). HCV-
infected women reporting current opiate use had the highest diabetes incidence (4.83 cases/100
person-years).
Conclusions—Among women with or at-risk for HIV, opiate use is associated with increased
diabetes risk independently of HCV infection. Diabetic screening should be part of care for opiate
users, and those infected with HCV.
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Introduction
Rates of diabetes mellitus are high in HIV-infected women and men, a relationship that has
been reported to be due, in part, to use of antiretroviral therapy (ART) and hepatitis C virus
(HCV) infection.1-4 Opiate use is often common in such patients,5,6 and has been linked to
perturbations in glucose metabolism in limited studies of animals and humans.7-11 Little is
known about the contribution of opiate use to the risk of diabetes among individuals with or
at-risk for HIV infection. We examined the associations of opiate use and HCV infection
with the prevalence and incidence of diabetes in a well-characterized cohort of HIV-infected
and at-risk uninfected women.
Methods
Study participants
The Women’s Interagency HIV Study (WIHS) is a prospective cohort study that enrolled
2,793 HIV-seropositive and 975 seronegative women at risk for HIV infection from six
inner-city sites in 1994-95 or 2001-02. Recruitment methods and data collection procedures
for the WIHS have been previously described.12,13 Briefly, participants were followed at
semi-annual research visits, during which blood was obtained for laboratory tests, a physical
exam was conducted, and an interviewer-administered questionnaire was completed to
ascertain sociodemographic characteristics, medical and family history, medication use, and
substance use behaviors. The protocol was approved by the Institutional Review Boards for
the protection of human subjects at each study site, and all participants provided written
informed consent.
Beginning in October 2000, plasma glucose levels were obtained at the study visit after
fasting for ≥8 hours. Of 2,859 WIHS participants with a study visit between October 2000
and March 2006, 2,554 had at least one fasting glucose measurement; the first visit with
fasting glucose data available was defined as the index visit. We excluded women who were
pregnant (n=60) or did not have pregnancy data (n=7) at the index visit, and those without
HCV data (n=122), resulting in 2,365 included women.
Laboratory measures
HCV serology was performed at WIHS enrollment using the Abbott HCV EIA 2.0 or 3.0
(Abbott Laboratories, Abbott Park, IL). As previously described,14 HCV RNA was
measured on frozen specimens from HCV-seropositive women using either the COBAS
Amplicor Monitor 2.0 assay (Roche Diagnostics, Branchburg, NJ) which has a linear range
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of 600 – 5 × 105 IU/ml, or the COBAS Taqman assay (Roche Diagnostics, Branchburg, NJ),
which has a linear range of 10 - 2.0 × 108 IU/ml. Extensive testing demonstrated
concordance in results between the two assay systems (data not shown). Fasting specimens
for glucose determination were collected in tubes with glycolytic inhibitors and stored at
−70° C. Plasma glucose was measured at a central laboratory using the hexokinase method.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured by
standard methodology in Clinical Laboratory Improvement Amendments (CLIA)-certified
laboratories.
Assessment of predictor variables
The primary predictor variables evaluated were opiate use and HCV infection. Past opiate
use was defined as self-reported use of heroin or methadone (licit or illicit) at any visit
between baseline and that prior to the index visit. Current opiate use at each visit was
defined as self-reported opiate use since the previous visit. HCV infection was defined as
being HCV seropositive and having detectable plasma HCV RNA. Other covariates
considered included age, race/ethnicity, body mass index (BMI), family history of diabetes,
AST, ALT, and HIV/ART status. BMI was categorized based on National Heart, Lung, and
Blood Institute guidelines: <25 kg/m2 (normal), 25-29.9 kg/m2 (overweight), and ≥30 kg/m2
(obese).15 ART regimens were classified as no therapy, monotherapy or combination
therapy, PI-based HAART, and non-PI-based HAART. The WIHS uses a standard
definition of HAART16 adapted from the Department of Health and Human Services/Kaiser
Panel guidelines.17
Diabetes Mellitus Ascertainment
Prevalent diabetes was defined as a fasting plasma glucose ≥126 mg/dl at the index visit, or
a self-report of either diabetes medication use or a diabetes diagnosis at or prior to the index
visit. For those who did not have prevalent diabetes at the index visit, incident diabetes was
defined as having at a study visit subsequent to the index visit either 1) a fasting plasma
glucose ≥126 mg/dl; 2) a self-report of diabetes medication use; or 3) a self-report of a
diabetes diagnosis with subsequent corroboration by either a fasting glucose ≥126 mg/dl or
reported diabetes medication use.
Statistical Analysis
Prevalent Diabetes—Univariate associations of participant characteristics were
determined with the chi-square or Wilcoxon tests, as appropriate. Multivariate logistic
regression analysis was used to identify independent predictors of prevalent diabetes.
Corresponding odds ratios (ORs) and 95% confidence intervals (CIs) were computed. All
models adjusted for the potentially confounding effects of variables measured at the index
visit. Specifically, adjustment was made for HIV/ART status and classic diabetes risk
factors, including age, race/ethnicity, family history of diabetes, and BMI. Analyses were
performed in 3 steps. In addition to the covariates listed above, model 1 included past opiate
use; model 2 included HCV infection; and model 3 included both past opiate use and HCV
infection.
Incident Diabetes—Proportional hazard regression analysis was performed to determine
predictors of diabetes incidence. Time at risk began at the index visit and terminated at the
end of the study period, report of pregnancy, or new onset diabetes, whichever occurred
first. Analyses were performed in 3 steps. In addition to HIV/ART status and the diabetes
risk factors listed above, model 1 included current opiate use as a time-dependent variable;
model 2 included HCV infection; and model 3 included current opiate use and HCV
infection.
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To assess for potential bias associated with misclassification of diabetes, we repeated the
prevalent diabetes multivariate logistic regression models excluding women with prevalent
diabetes defined only by a self-reported diagnosis of diabetes. We also repeated all models
(prevalent and incident diabetes) excluding 1) HCV seropositive women with an
undetectable HCV RNA, because without an HCV RNA level at a second point in time, it
was not possible to determine with certainty whether these women did or did not have
persistent HCV infection;18 and 2) women who reported use of interferon and/or ribavirin
for hepatitis C, because HCV treatment has been associated with changes in glucose
tolerance.19,20 Due to the skewness of HCV RNA level that could not be corrected by other
transformations, in models that assessed the association of HCV RNA level with diabetes
risk, a continuous variable with numerical values of 0, 1, 2, and 3 was created indicating the




Participant characteristics are listed in Table 1. Of 2,365 WIHS women with an index visit,
464 (20%) women reported a history of opiate use at any visit prior to the index, of whom
130 (5%) reported heroin or illicit methadone use only, 129 (5%) reported methadone
maintenance therapy only, and 205 (9%) reported both illicit opiate use and methadone
maintenance therapy. Two-thirds of the past opiate users also reported a history of crack
and/or cocaine use, and 42% (n=197) reported current opiate use. Compared to women who
did not use opiates, opiate users were older and more often HCV-infected, but had a similar
HIV seroprevalence.
A total of 612 (26%) women were HCV seropositive and 470 (20%) had active HCV
infection, as determined by a detectable HCV RNA level. Compared with HCV-uninfected
women, HCV-infected women were older, more often African American and HIV-infected,
and less likely to be obese. HCV-infected women had higher ALT and AST levels and lower
albumin levels compared with HCV-uninfected women, but regardless of HCV status, the
majority of participants had transaminase and albumin levels within the normal range. A
small minority of women (n=70) reported use of interferon and/or ribavirin for hepatitis C.
Prevalent Diabetes
A total of 259 (11%) women had prevalent diabetes at the index visit, of whom 115 (44%)
had a fasting glucose ≥126 mg/dl, 49 (19%) reported diabetes medication use and 95 (37%)
reported a diabetes diagnosis at or prior to the index visit. The prevalence of diabetes was
higher among past opiate users compared to nonusers (18% vs. 9%, p<.001) (Table 2).
Prevalent diabetes was more common among women who reported a history of either opiate
use alone (36 of 155, 23%) or both opiate and crack/cocaine use (49 of 309, 16%) compared
with women who reported only crack/cocaine use (31 of 304, 10%) or no drug use (143 of
1597, 9%). Because the association between past opiate use and diabetes was not modified
by crack/cocaine use, opiate users who did and did not use crack/cocaine were combined for
all subsequent analyses. The prevalence of diabetes was also greater among current opiate
users compared to nonusers (15% vs. 10%, p=.03), and women with HCV infection
compared with those without (16% vs. 10%, p=.0004). When current prescription narcotic
use was included as a covariate, we found an association with prevalent diabetes (OR 1.72,
95% CI 1.14, 2.61), and when combined with illicit opiate use/methadone, strengthened the
association of current opiate use with prevalent diabetes (OR 2.58, 95% CI 1.10, 6.07).
Among HCV-infected women, there was no association between levels of AST (OR 1.00
per 5 U/L, 95% CI 0.97, 1.03) or ALT (OR 1.00 per 5 U/L, 95% 0.97, 1.03) and prevalent
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diabetes. There was no pattern in diabetes prevalence or statistically significant associations
by HIV infection or ART use at index visit.
Table 2 shows the results of three models for the association between past opiate use, HCV
infection, and prevalent diabetes. After adjusting for age, race/ethnicity, family history of
diabetes, BMI, and HIV/ART status (Model 1), past opiate use remained associated with
prevalent diabetes (ORadj 1.69, 95% CI 1.24, 2.31). In a separate model (Model 2) adjusting
for the same covariates, the association between HCV infection and prevalent diabetes was
no longer significant (ORadj 1.27, 95% CI 0.92, 1.75). When both past opiate use and HCV
infection were included in the same model (Model 3), the association between HCV and
prevalent diabetes was further attenuated (ORadj 0.97, 95% CI 0.67, 1.41), while the
association between past opiate use and prevalent diabetes remained the same (ORadj 1.71,
95% CI 1.20, 2.45). Other factors associated with prevalent diabetes in this model included
older age (ORadj 1.06 per year, 95% CI 1.04, 1.08), family history of diabetes (ORadj 1.77,
95% CI 1.34, 2.34), and BMI ≥ 30 kg/m2 (ORadj 3.21, 95% CI 2.28, 4.50; reference <25.0
kg/m2). The point estimates for the multivariate models were essentially unchanged when
we excluded women in whom diabetes was defined by self-report only, those who were
HCV seropositive and had an undetectable HCV RNA level, or those who reported use of
interferon and/or ribavirin for hepatitis C (data not shown).
Incident Diabetes
Among the 2,365 women analyzed above, 2,106 did not have prevalent diabetes at the index
visit, and of these 2,016 (96%) had a fasting glucose level measured at a subsequent study
visit and were thus included in the analysis of incident diabetes. The median duration of
follow-up of 3.47 years (IQR 2.22, 4.41) did not differ by HCV status (p=.60). New-onset
diabetes was observed in 145 women, of whom 94 (65%) were defined by a fasting plasma
glucose ≥126 mg/dl at a study visit, 44 (30%) by self-report of diabetes medication use, and
7 (5%) by self-report of diabetes diagnosis with subsequent corroboration with either a
fasting glucose ≥126 mg/dl or reported diabetes medication use.
Incidence rates of diabetes stratified by past opiate use, current opiate use, and HCV
infection status are shown in Table 3. Women with a history of opiate use (past or current)
had a higher diabetes incidence (3.68/100 person-years, 95% CI 2.66, 4.96 and 3.57/100
person-years, 95% CI 2.21, 5.45, respectively) than did non-users (1.89/100 person-years,
95% CI 1.54, 2.29 and 2.07/100 person-years, 95% CI 1.72, 2.47, respectively). Similarly
HCV-infected women had a higher diabetes incidence (3.68/100 person-years, 95% CI 2.70,
4.91) than did HCV-uninfected women (1.86/100 person-years, 95% CI 1.51, 2.26). HCV-
infected women who reported current opiate use had the highest diabetes incidence
(4.83/100 person-years, 95% CI 2.81, 7.73).
Table 4 shows the results of three proportional hazards regression models for the association
between HCV infection, current opiate use, and incident diabetes. In models controlling for
classic diabetes risk factors and HIV/ART status, current opiate use and HCV infection were
associated with the development of diabetes: for current opiate use (Model 1) RHadj 1.89
(95% CI 1.27, 2.80); and for HCV infection (Model 2), RHadj 1.78 (95% CI 1.22, 2.61). Due
to the positive association between current opiate use and HCV infection, both of these
hazard ratios were attenuated when current opiate use and HCV infection were entered into
the same model (Model 3). Factors remaining associated with incident diabetes in this final
model included current opiate use (RHadj 1.58, 95% CI 1.01, 2.46), age (RHadj 1.04 per
year, 95% CI 1.02, 1.06), family history of diabetes (RHadj 1.64, 95% CI 1.16, 2.32) and
BMI ≥30 kg/m2 (RHadj 3.06, 95% CI 1.96, 4.78; reference BMI <25 kg/m2). These point
estimates were essentially unchanged when we excluded HCV seropositive women with an
undetectable HCV RNA level from the fully adjusted model. When women who reported
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use of interferon and/or ribavirin for hepatitis C were excluded from the fully adjusted
model, the association between HCV and incident diabetes reached statistical significance
(RHadj 1.61, 95% CI 1.02, 2.52). HIV/ART status was not associated with incident diabetes
in any model.
Among HCV-infected women, increasing HCV RNA quartiles appeared to be associated
with new-onset diabetes (HR 1.30 per quartile, 95% CI 0.97, 1.73), however this association
may be due to chance. Among HCV-infected women, there was no association between
AST and ALT levels and incident diabetes (data not shown).
Discussion
In this large ethnically-diverse cohort of women with or at-risk for HIV infection, past
opiate use was associated with increased diabetes prevalence independent of HCV infection,
HIV status, or antiretroviral use. In addition, current opiate use was independently
associated with an increased risk of incident diabetes. Among current opiate users, women
infected with HCV had a higher diabetes incidence than did women who were uninfected.
While classic diabetes risk factors, including older age, obesity and a family history of
diabetes were also predictive of diabetes, the association of recent ART use with diabetes
was not statistically significant.
To our knowledge, this is the first study to use prospectively collected data to investigate the
possible opiate-diabetes relationship. Prior cross-sectional studies have reported associations
between opiate use and disordered glucose metabolism, however they did not control for
HCV status, which may have confounded the observed relationship. In the Menopause
Study, a cohort of mid-life women with or at-risk for HIV infection, methadone use was
found to be associated with prevalent diabetes, with an increased odds of diabetes for each
quartile of current methadone dose.21 This study also found that current opiate use (heroin
or methadone) was associated with lower insulin secretion, estimated using the 30-minute
incremental ratio of insulin to glucose. A similar study in CHAMPS, a comparable cohort of
men with or at-risk for HIV infection, also found an independent association between
methadone use and prevalent diabetes.22 Furthermore in this cohort, a history of heroin use
was associated with greater insulin resistance. Several small studies of HIV-uninfected
patients have also demonstrated an association between opiate use and abnormal glucose
metabolism. One study suggested that opiate use may induce insulin resistance, as higher
insulin levels while fasting and after an oral glucose load were observed in heroin users
compared to healthy controls.9 Other studies have reported a lower acute insulin response
after an intravenous glucose load in heroin users compared to control subjects, suggesting
impaired beta cell function.10,11 Abnormal glucose tolerance has also been observed in
experimental studies of methadone-addicted rats.7
While these data provide further evidence that opiate use may affect glucose metabolism,
the fact that certain studies point to beta cell dysfunction, and other studies to effects on
insulin sensitivity, leaves the mechanisms uncertain. In animal models, morphine
administration was found to induce glucagon release, suggesting that opiates may exert a
direct effect on the pancreas, resulting in hepatic glucose output.8 Another animal study
found that opiate-induced glucose intolerance was accompanied by both a reduction in the
activity of specific glycolytic enzymes, and an elevation in the activity of gluconeogenic
enzymes in the liver of exposed animals.7 Further experimental data suggest that opiates can
inhibit insulin signaling through direct cross talk between downstream signaling pathways of
the μ-opioid receptor and the insulin receptor.23
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Prior studies have found that HCV infection is associated with disorders of glucose
metabolism, particularly among individuals at increased risk of diabetes due to greater age
and/or BMI.24,25 We found that HCV infection, as well as greater HCV RNA levels,
appeared to be positively associated with incident diabetes, although the associations were
not statistically significant in all models. One retrospective cohort analysis of 1149 HIV-
infected persons on HAART over a median follow-up of 8.9 months found a two-fold
increase in hyperglycemia incidence among HCV-infected persons (4.9 cases/100 person-
years) compared with uninfected persons (2.3 cases/100 person-years).3 Unlike the present
study, that study did not adjust for family history of diabetes, a key diabetes risk factor, and
did not obtain glucose levels systematically for all cohort members, which may have
resulted in selection bias. Biological evidence to support an association between HCV and
diabetes include several studies demonstrating that HCV proteins interfere with insulin
signaling.26-28 In addition HCV RNA has been identified in pancreatic tissue of HIV/HCV
co-infected patients, suggesting that HCV may have a direct influence on islet cell function.
29
We did not find a strong association between ART status and incident diabetes when
compared to HIV-uninfected women, in contrast to another study in men, which did not
control for several key factors associated with diabetes including family history of diabetes
and HCV status.1 Our findings may also be partially attributable to changing patterns of
antiretroviral use, as newer PIs have less of an effect on insulin sensitivity than indinavir,
30-32 which was commonly used early in the HAART era. Among HIV-infected individuals,
cumulative exposure to nucleoside reverse transcriptase inhibitors (NRTIs) has been
associated with risk of diabetes incidence and insulin resistance,2,33 which may be
attributable to NRTI-induced mitochrondrial dysfunction.34
The strengths of our study include the prospective design, the availability of fasting glucose
levels to define diabetes, and the use of HCV RNA levels as an indicator of persistent HCV
infection. Inclusion of data on family history of diabetes also allowed us to adjust for this
important risk factor. Furthermore, our analysis was strengthened by inclusion of an HIV-
uninfected comparison group with a similar demographic and behavioral profile.
Our study also has certain limitations. First, as in other analyses of diabetes in HIV cohorts,1
we defined diabetes based on a single fasting glucose measurement, rather than after
confirmation on a subsequent day as recommended by the American Diabetes Association.35
Second, we were not able to distinguish whether diabetes medications were used to treat
diabetes or for other reasons such as to treat insulin resistance or changes in fat distribution
associated with HIV infection. In addition, we only measured plasma HCV RNA in HCV
seropositive women. Recent data suggest that some HCV seronegative HIV-infected
individuals may have detectable HCV RNA, particularly in the setting of a low CD4+ count.
36 Therefore, some HCV-infected women may have been misclassified. Finally, the findings
in our cohort of predominantly African American and Hispanic women may not apply to
HIV-infected populations with different sociodemographic characteristics. However given
that drug use, HCV infection and diabetes all disproportionately affect these racial and
ethnic groups,37,38 understanding the association of these disorders in this population is of
great importance.
In summary, we observed that opiate use was associated with increased diabetes prevalence
and incidence among HIV-infected and at-risk-uninfected women, independent of HCV
infection or antiretroviral use. HCV infection also appeared to increase the risk of incident
diabetes. Based on our findings, routine monitoring of fasting glucose levels in women with
or at-risk for HIV infection who use opiates or have persistent HCV infection may be
warranted.
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Table 4
Unadjusted and adjusted relative hazards of incident diabetes among 2,016 womena
Variable Unadjusted RH(95% CI)
Adjusted RH (95% CI)
Model 1 Model 2 Model 3
Current opiate use 2.04 (1.41, 2.96)b 1.89 (1.27, 2.80)c --- c 1.58 (1.01, 2.46)d
HCV infected 2.02 (1.43, 2.87)b --- d 1.78 (1.22, 2.61)c 1.48 (0.96, 2.28)
Age (per year) 1.05 (1.03, 1.07)f 1.04 (1.02, 1.07)f 1.04 (1.02, 1.06)f 1.04 (1.02, 1.06)b
Race/ethnicity
 African American 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 Hispanic 0.79 (0.53, 1.17) 0.87 (0.57, 1.31) 0.94 (0.62, 1.43) 0.90 (0.59, 1.37)
 Caucasian 1.09 (0.68, 1.76) 1.24 (0.74, 2.06) 1.28 (0.77, 2.13) 1.26 (0.76, 2.10)
 Other 0.17 (0.02, 1.24) 0.27 (0.04, 1.92) 0.28 (0.04, 2.02) 0.27 (0.04, 1.96)
Family history of diabetes 1.91 (1.37, 2.66)c 1.65 (1.17, 2.33)d 1.68(1.19, 2.36)d 1.64 (1.16, 2.32)d
Body mass index (kg/m2)
 Normal (<25.0) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 Overweight (25.0-29.9) 0.89 (0.56, 1.41) 1.58 (0.96, 2.58) 1.64 (1.00, 2.68) 1.64 (1.00, 2.68)
 Obese (≥ 30) 1.70 (1.15, 2.51)d 2.93 (1.88, 4.56)e 3.01 (1.92, 4.71)e 3.06 (1.96, 4.78)e
HIV/ART status
 HIV uninfected 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 HIV infected
  No therapy 0.89 (0.54, 1.47) 0.94 (0.56, 1.58) 0.89 (0.53, 1.49) 0.91 (0.54, 1.53)
  Mono/combination therapy 1.17 (0.52, 2.64) 1.19 (0.52, 2.74) 1.06 (0.46, 2.43) 1.14 (0.49, 2.63)
  Non-PI HAART 1.55 (0.98, 2.45) 1.67 (1.02, 2.73)d 1.52 (0.93, 2.47) 1.61 (0.98, 2.64)
  PI-HAART 1.32 (0.83, 2.10) 1.19 (0.71, 1.97) 1.11 (0.67, 1.84) 1.15 (0.69, 1.92)
a
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